Dimitrios Arkilo named CMO of Actio

Actio Biosciences Inc. hired Dimitrios Arkilo to succeed CMO Sam Collins, who will become a consultant to the company. Arkilo was VP of medical science at Sage Therapeutics Inc. (NASDSAQ:SAGE). Actio aims to leverage the target biology revealed by the strong genetic perturbations that drive rare diseases to treat a wider range of pathologies with shared phenotypic signatures.

Treg therapies company Coya Therapeutics Inc. (NASDAQ:COYA) promoted CBO Arun Swaminathan to CEO, effective Nov. 1. Swaminathan succeeds Howard Berman, who will continue as executive chair. ...